drugset / Trial / NCT02290470
Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel
RandomizedParallel-groupOpen-labelSupportive care
Summary
This randomized, pilot study explores the activity of olanzapine with or without delayed dexamethasone for the prevention of delayed nausea and vomiting in women with gynecologic cancer receiving the combination of carboplatin and paclitaxel. Women treated with this regimen are particularly susceptible to chemotherapy-induced nausea and vomiting. Given anti-emetic prophylaxis with olanzapine may increase the control of delayed symptoms in women receiving carboplatin and paclitaxel.
Timeline
- Start
- 2014-04
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 4 mg | Intravenous |
| Subject | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Subject | Dexamethasone | Small molecule | 16 mg | Intravenous |
| Subject | Olanzapine | Small molecule | 10 mg | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
Indications
No indication recorded.